Why Is Neurocrine Biosciences Stock Trading Lower Today?

Thursday, Neurocrine Biosciences Inc NBIX released Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia.

The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc XENE, failed to demonstrate meaningful seizure frequency reduction in the Phase 2 dose-finding study as adjunctive therapy in adults with focal onset seizures. 

No further development with NBI-921352 in Focal Onset Seizure (FOS) is currently planned. 

Neurocrine is reviewing the data from the FOS study to understand any potential implication for its ongoing study in SCN8A-developmental epileptic encephalopathy and will provide an update once this review is complete. 

The investigational NBI-1065846, as part of the collaboration with Takeda Pharmaceutical Company Limited TAK, did not meet its primary endpoint in the Phase 2 TERPSIS study evaluating its efficacy compared to placebo in patients with anhedonia in major depressive disorder. 

No further development with NBI-1065846 is planned at this time. 

Neurocrine and Takeda continue to collaborate on several programs in clinical development, including NBI-1065845 for inadequate response to treatment in major depressive disorder (Phase 2), luvadaxistat for cognitive impairment associated with schizophrenia (Phase 2), and NBI-1070770 for major depressive disorder (Phase 1).

Mizuho lowered the price target from $116 to $144 and maintains the Neutral rating.

The analyst removed risk-adjusted revenues for NBI-921352 in FOS and NBI-1065846 in Anhedonia.

The analyst says the targeted sodium channel inhibition with NBI-921352 could have a better chance of showing a clear signal in SCN8A-DEE when the trial reads out in 2024, as SCN8A-DEE is caused by a gain-of-function mutation of the NaV1.6 sodium channel, which is NBI-92135's target. 

Price Action: NBIX shares are down 5.50% at $105.98 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversGeneralBiotechnologyBriefsHealth Carewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!